Endocrine Society backs a $20 billion push to narrow the women’s health gap
Women still enter the health system with too many unanswered questions, and endocrine care sits squarely inside that gap. On Sept. 29, the Endocrine Society joined the Society for Women’s Health Research, the American College of Obstetricians and Gynecologists, the Women First Research Coalition, and other organizations on Capitol Hill to press Congress to support the National Strategy to Close the Women’s Health Gap.
The coalition is calling for a bold, strategic $20 billion, 10-year investment in women’s health research. The funding target is not symbolic. It is designed to move women’s health from a fragmented collection of underfunded programs into a coordinated national priority spanning discovery, regulation, implementation, and public education.
The political setting matters because endocrine disorders often show how badly women’s health evidence has lagged behind clinical need. Hormonal transitions, reproductive life stages, autoimmune burden, metabolic disease, and bone health all intersect in ways that are not captured well by legacy research models. When women are underrepresented, clinicians inherit a thinner evidence base, and that weakness travels directly to bedside decisions.
The National Strategy, unveiled in July and already endorsed by more than 20 organizations, aims to close the gap across five priority areas: research and innovation, regulatory coordination and modernization, data and evidence infrastructure, bolstering the women’s health clinical and research workforce, and public awareness and education. Each of those pillars addresses a different failure point. Together, they describe a system that has not only underinvested in women’s health, but also struggled to translate evidence into routine care.
One of the strongest arguments for the strategy is historical. The National Institutes of Health Revitalization Act of 1993 required women to be included in NIH-funded clinical research, a milestone that changed the rules of enrollment. Yet inclusion alone did not erase the deeper problem: gaps in research questions, study design, evidence generation, and implementation have persisted for decades. Women can be present in a trial and still remain poorly studied if investigators do not measure the outcomes that matter most across female life stages.
That problem is especially visible in endocrine medicine, where sex hormones shape disease expression, treatment response, and risk over time. A research agenda that does not account for menopause, pregnancy, postpartum physiology, thyroid disease patterns, or sex-based cardiometabolic differences leaves clinicians with incomplete guidance. In practice, that means delayed diagnosis, weaker risk stratification, and treatment pathways that may have been built around male-dominant datasets.
The Endocrine Society’s participation also reflects a broader policy reality: women’s health is not a single specialty issue. It cuts across internal medicine, obstetrics and gynecology, endocrinology, cardiology, psychiatry, and public health. A national strategy can only work if Congress treats the problem as structural rather than episodic, and if federal agencies align research funding, regulatory standards, and data systems around a common objective.
A stronger evidence base would also affect how trials are interpreted. Endpoints that appear straightforward in mixed populations can behave differently when outcomes are measured by sex, age, hormonal status, or disease stage. Better data infrastructure would make it easier to identify where therapies work well, where safety signals differ, and which subgroups need tailored management instead of one-size-fits-all protocols. That is especially important in chronic endocrine disease, where treatment often unfolds over years rather than weeks.
At the Capitol Hill meetings, the organizations’ message centered on education as much as funding. Policymakers were asked to understand that women’s health research is not peripheral spending. It is a prerequisite for accurate diagnosis, effective prevention, and durable treatment strategies. Without that commitment, progress remains uneven: some conditions advance quickly while others continue to rely on small datasets, outdated assumptions, or extrapolation from studies that were never designed to answer women-specific questions.
The coalition’s strategy also places unusual emphasis on the workforce. That piece is easy to miss, but it is clinically important. More investigators, clinicians, and implementation experts focused on women’s health would expand the number of studies launched, the range of questions asked, and the speed at which evidence reaches practice. A thin workforce slows every stage of the pipeline, from grant submission to community delivery.
Public awareness belongs in the same framework because patients cannot advocate for care they do not know they need. Too many symptoms of endocrine disease are normalized, dismissed, or attributed to stress, aging, or nonspecific illness. Better education can shorten the time from symptom onset to diagnosis and improve demand for appropriate screening, follow-up, and specialty referral.
The strategy now sits at a familiar but consequential junction: endorsement has been secured, and the next hurdle is whether Congress treats the proposal as a serious investment in evidence generation rather than as a narrow advocacy ask. For endocrinology, the stakes are concrete. Better women’s health research would directly affect how clinicians study and manage metabolic disease, thyroid disorders, reproductive endocrinology, menopause-related changes, and the long tail of chronic disease burden that women carry across the lifespan. The unfinished question is whether federal policy will match the scale of that burden with an equally durable research commitment.